When Patients Say No – Outcomes of Opting Against Recommended Treatment After Total Neoadjuvant Therapy for Stage II/III Rectal Cancer

Authors

Scarlett B. Hao, Corewell Health East Fellow
Jacob Applegarth, Corewell Health East Resident
Erin Mueller, Corewell Health East Resident
Harry Wasvary, Corewell Health East
Matthew Ziegler, Corewell Health East
Bradley Krasnick, Corewell Health East

Document Type

Conference Proceeding

Publication Date

5-11-2025

Abstract

Patients with stage II/III rectal cancer, upon completion of total neoadjuvant therapy (TNT), may be recommended total mesorectal excision (TME) or a watch-and-wait (WW) approach depending on their clinical tumor response. However, in shared decision-making, patients may ultimately decide for surgery when it is not recommended or against surgery when it is recommended. This study aimed to describe the tumor response outcomes of patients with LARC who pursue and do not pursue the recommended approach following TNT.

Comments

ASCRS 2025 Annual Scientific Meeting, San Diego, California, May 10-13, 2025.

Recommended Citation

Hao SB, Applegarth J, Mueller E, Wasvary H, Ziegler M, Krasnick B. When patients say no – outcomes of opting against recommended treatment after total neoadjuvant therapy for stage II/III rectal cancer. Paper presented at: ASCRS 2025 Annual Scientific Meeting; 2025 May 10-13; San Diego, CA.